Overview

Phase I/Ⅱa Study of BR790 in Combination With Anlotinib in Adult Subjects With Advanced Non-Small Cell Lung Cancer

Status:
Not yet recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
This is a Phase I/Ⅱa, multi-center, open-label study, aiming to evaluate the safety, tolerability, pharmacokinetic (PK), and efficacy of BR790 in combination with anlotinib in adult participants with advanced NSCLC.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Shanghai Gopherwood Biotech Co., Ltd.